Quadrivalent meningococcal conjugate vaccines.

Journal article

Neisseria meningitidis is an important cause of bacterial meningitis and septicaemia with most disease caused by meningococci bearing serogroups A, B, C, Y and W-135 polysaccharides. Monovalent serogroup C conjugate vaccines have become established in the immunisation programmes in many countries and the first quadrivalent meningococcal vaccine, containing the polysaccharides from 4 of the serogroups A, C, Y and W-135 meningococci conjugated to a protein carrier was licensed in the US in 2005. This vaccine and others in development offer the potential to broaden population protection against meningococcal disease.

Authors: Pace, D; Pollard, A; Messonier, N

• Publication status: Published
• Journal: Vaccine
• Volume: 27 Suppl 2
• Issue: SUPPL. 2
• Pages: B30-B41
• Publication date: 2009-06-01
• DOI: 10.1016/j.vaccine.2009.05.003
• EISSN: 1873-2518
• ISSN: 0264-410X
• Language: English
• Keywords: Neisseria meningitidis, Serogroup W-135; Neisseria meningitidis, Serogroup A; Humans; Vaccines, Conjugate; Meningitis, Meningococcal; Neisseria meningitidis, Serogroup B; Meningococcal Vaccines; Neisseria meningitidis, Serogroup C; Sepsis; United States